Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Y-mAbs Therapeutics, Inc. - Common Stock
(NQ:
YMAB
)
5.250
+0.400 (+8.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 6, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Y-mAbs Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
S&P 500 Down 0.5%; Crude Oil Falls Sharply
October 31, 2022
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping around 0.5% on Monday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
October 31, 2022
During Monday's session, 96 stocks hit new 52-week lows.
Via
Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
October 31, 2022
Within the last quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 31, 2022
Gainers
Via
Benzinga
Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session
October 31, 2022
Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its...
Via
Benzinga
Nasdaq Down Over 100 Points; Chicago PMI Drops Further
October 31, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
US Stocks Start Week On Lower Note; Dow Dips Over 200 Points
October 31, 2022
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Monday.
Via
Benzinga
Grainger To Surge Over 11%? Plus This Analyst Predicts $230 For Caterpillar
October 31, 2022
UBS raised the price target on Caterpillar Inc. (NYSE: CAT) from $225 to $230. Caterpillar shares fell 1.1% to $216.85 in pre-market trading.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 31, 2022
Gainers PLx Pharma (NASDAQ:PLXP) stock increased by 15.5% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $20.3 million.
Via
Benzinga
TuSimple, Y-mAbs Therapeutics And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
October 31, 2022
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 31, 2022
Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning!
Via
InvestorPlace
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket
October 31, 2022
Gainers Selina Hospitality PLC (NASDAQ: SLNA) rose 31.9% to $19.90 in pre-market trading after dipping around 63% on Friday.
Via
Benzinga
FDA's AdComm Gives Thumbs Down To Pediatric Cancer Therapy
October 31, 2022
FDA's Oncologic Drugs Advisory Committee (ODAC) raised concerns regarding the efficacy of Y-mAbs Therapeutics Inc's (NASDAQ: YMAB) potential pediatric neuroblastoma treatment, omburtamab.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 27, 2022
Gainers
Via
Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 27, 2022
From
The Schall Law Firm
Via
Business Wire
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
October 28, 2022
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also...
Via
Benzinga
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session
October 27, 2022
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process...
Via
Benzinga
Lost Money in Y-mAbs Therapeutics, Inc.?
October 26, 2022
From
Gibbs Law Group
Via
Business Wire
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
October 27, 2022
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the...
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 26, 2022
From
The Schall Law Firm
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 26, 2022
Gainers
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
September 01, 2022
Via
Benzinga
FDA Advisory Committee Meeting Scheduled For October 28, 2022 To Review Y-mAbs' Refiling For Omburtamab
September 01, 2022
The Oncologic Drugs Advisory Committee (ODAC) of the U.S.
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
August 30, 2022
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
June 24, 2022
Upgrades
Via
Benzinga
Earnings Scheduled For August 8, 2022
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
103 Biggest Movers From Yesterday
May 11, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.